Skip to main content Accessibility help
×
Hostname: page-component-78c5997874-94fs2 Total loading time: 0 Render date: 2024-11-10T14:12:43.312Z Has data issue: false hasContentIssue false

18 - Genetic variation and drug dependence risk factors

from Part V - Specific psychotropic drugs and disorders

Published online by Cambridge University Press:  20 August 2009

Joel Gelernter
Affiliation:
Yale University School of Medicine and VA CT Healthcare Center, West Haven, USA
Henry Kranzler
Affiliation:
University of Connecticut School of Medicine, Farmington, USA
Bernard Lerer
Affiliation:
Hadassah-Hebrew Medical Center, Jerusalem
Get access

Summary

OVERVIEW

This chapter discusses pharmacogenetics in the context of substance abuse and dependence. Owing to the nature of substance-dependence disorders – an exogenous substance is ingested – there is virtually always potential for direct interaction with pharmacogenetic factors, many of which would be expected to be specific to the substance of abuse. Several well-understood examples of such factors are discussed. These issues are placed in the context of identifying and understanding broader genetic risk factors for substance dependence, and of guiding development of pharmacological treatments, both for all patients abusing a given class of substance, and for individual patients based on their specific biochemical make-up as predicted by genetic polymorphism.

Introduction

Genetic factors are important contributors to risk for substance dependence. Some are specific to the substance (e.g., resulting in different euphoric effects by individual), and some are more general (e.g., personality features – novelty seeking, anti-social personality, and so on – which may influence exposure to substances or the transition from substance use to dependence). While the factors that might be mediated by personality and behavior can be conceptualized as analogous to genetic risk factors for other classes of psychiatric disorder, those that are specific to the abused substance could reflect a different set of mechanisms involving genetic variability in receptor–ligand interaction or metabolism of the substance. This can be illustrated by considering two hypothetical limiting cases.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2002

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×